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Abstract. Predictive epidemiological models are able to be used most
effectively when they have first been shown to fit historical data. Finding
the right parameters settings for a model is complex: the system is likely
to be noisy, the data points may be sparse, and there may be many
inter-related parameters. We apply computational intelligence and data
mining techniques in novel ways to investigate this significant problem.
We construct an original computational model of human papilloma virus
and cervical intraepithelial neoplasia with the ultimate aim of predict-
ing the outcomes of varying control techniques (e.g. vaccination, screen-
ing, treatment, quarantine). Two computational intelligence techniques
(genetic algorithms and particle swarm optimisation) are used over one-
stage and two-stage optimisations for eight real-valued model parame-
ters. Rigorous comparison over a variety of quantitative measures demon-
strates the explorative nature of the genetic algorithm (useful in this pa-
rameter space to support the modeller). Correlations between parameters
are drawn out that might otherwise be missed. Clustering highlights the
uniformity of the best genetic algorithm results.
Prediction of gender-neutral vaccination with the tuned model suggests
elimination of the virus across vaccinated and cross-protected strains,
supporting recent Scottish government policy. This preliminary study
lays the foundation for more widespread use of computational intelligence
techniques in epidemiological modelling.
Keywords: genetic algorithm · particle swarm optimisation · epidemi-
ology · human papilloma virus · k-means clustering.
1 Scientific Background
Computational models are increasingly used to investigate complex biological
systems such as disease spread and the effects of interventions such as vaccina-
tion and treatment. Choosing parameters for these models can be challenging. A
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small change to a parameter value or the model structure can be the difference
between a large outbreak, endemic disease, or elimination of the disease. Com-
putational intelligence approaches are highly suitable tools to support modellers
to fit a model to historical data, as shown in our previous work [1], and provide
a base for future predictions. We compare and contrast two such tools (genetic
algorithm (GA) and particle swarm optimisation (PSO)) in a realistic case study
of international importance. In addition, we extend our use of clustering tech-
niques with process algebra [2] to investigate the quality of the results of the
optimisation.
The Human Papillomavirus (HPV) is a sexually transmitted infection which
affects the skin and moist membranes of humans. There are over 200 strains of
this virus which are split into two subcategories known as oncogenic (high-risk)
and non-oncogenic (low-risk). Oncogenic strains of this virus play a pivotal role
in the development of various cell abnormalities including tumours [3]. Almost all
cases of cervical cancer in women are attributed to high-risk HPV strains [4]. The
World Health Organisation has made a global call to eliminate cervical cancer
worldwide [5], driven through better understanding of HPV control measures.
This paper contributes to that understanding by presenting computational
intelligence and data mining approaches to optimising a model of HPV and
pre-cancerous stages. The model is fitted to Scottish data to demonstrate the
techniques. According to Kavanagh et al. [6] 80% of cervical cancer cases in
Scotland are attributed to HPV 16 & 18. Females aged 12-13 have received a
bivalent vaccine against those strains since September 1st 2008 in Scotland. This
programme has reduced HPV 16 & 18 prevalence from 30% to 4% in females [6].
The bivalent vaccine provides cross-protection against strains HPV 31, 33 & 45;
however, that protection may reduce over time. Predictive modelling is used to
investigate equal vaccination policies and the effect of waning cross-protective
immunity.
As a starting point, we use a real-valued Genetic Algorithm (GA) as a
general-purpose heuristic solver and Particle Swarm Optimisation (PSO) as an
alternative solver that is useful for searching continuous parameter spaces. The
model has eight parameters, which is a modest challenge for the chosen op-
timisation techniques but has produced some unexpected observations of the
correlations between the parameters. The relationships between the optimal so-
lutions within and between each approach are further explored through the use
of data mining (clustering).
We use the optimised model to predict future outcomes of variants of the
vaccination programme. We predict that a gender-neutral vaccination program
can eradicate high-risk oncogenic strains of HPV even where immunity to those
strains wanes. This work establishes a framework for applying computational
intelligence to process algebra modelling, with effective and rigorous approaches
to evaluating the resulting solution set.
2 Materials and Methods
2.1 Tools
The Evolving Process Algebra toolkit (EPA) [1] was developed with the goal of
bridging the gap between evolutionary computation and the formal modelling
domain, specifically using process algebra for modelling due to its parsimony
and suitability for biological systems of interacting components. EPA is built on
the ECJ Evolutionary Computation toolkit and the Bio-PEPA (deterministic
or stochastic) simulation engine [7]. For this study, EPA was extended with a
parameter sweep component and a particle swarm optimisation (PSO) module,
complementing the existing GA approach to optimisation of numeric model pa-
rameters. EPA is able to optimise model structure and numeric parameters [1].
Here, the core aspects of the model are standard and only numeric parameters
need to be optimised.
2.2 Model
The HPV model is a classic SEIR (Susceptible, Exposed, Infected, Recovered
(Immune)) compartmental model [8] extended with binary gender and the po-
tential precursor stages of cervical cancer (three stages of cervical intraepithe-
lial neoplasia (CIN). Epidemiological studies [6, 9] informed model development.
Fig. 1 shows the compartments of the model and the available transitions be-
tween compartments. The Bio-PEPA code for the model is archived online [10].
There are over 200 strains of HPV. For this investigation our model groups
together the two oncogenic strains HPV16 and HPV18 which are targeted by
the bivalent vaccine. The cross-protected strains HPV 31, 33 and 45 (some level
of protection is conferred by the bivalent vaccine) are identified as “other” in
the model. Further strains of HPV have been omitted.
Vaccination has been added in a staged manner via a rolling vaccination
programme for girls aged 12-13 and a targetted catch-up programme for older
girls (14-18) (who may have already been exposed to HPV strains, so vaccination
may be unsuccessful). The catch-up programme ran for 3 years; in 2014, the
eligible routine age for vaccinations was amended to 11-12 year olds for logistical
purposes. The model gradually increases both vaccine takeup and vaccine efficacy
to capture these features. The timescale is one simulation tick per day, therefore
rate constants are expressed as daily rates. The population is open, with births,
deaths and immigration. The birth rate is chosen to balance up the death rate
in the Scottish population (keeping the population constant for the duration
of the study). Immigration (average number of imported infections per year) is
given by the standard formula 0.02
√
N , where N is the total population [13]. For
optimisation, the simulation time is seven years, matching the data of Kavanagh
et al [6]. The vaccine is introduced after the first simulation year.
HPV is a sexually-transmitted infection. Couplings are simplified as being
female-female, female-male, male-female, and male-male, in proportions reflect-










Fig. 1. Schematic of the HPV model showing compartments and routes between com-
partments. Birth is a source of new individuals. The compartments S, Exp, Inf, Immune
are prefixed f (females) and m (males). The suffix v or nv relates to vaccinated or
not vaccinated. HPV 16 and 18 are the Exp → Inf → Immune strands, and HPV 31,
33 and 45 have the suffix other. Three pre-cancerous stages CIN1, CIN2, CIN3 affect
females only.
fixed, reflecting fluidity of orientation and behaviours. This simplification is a
pragmatic modelling choice suiting the Markov chain semantics of Bio-PEPA.
The two routes from susceptible to exposed in Fig. 1, e.g. fS nv to fExp reflect
that the infection can come from a female or a male partner.
HPV can be described as using frequency-dependent transmission: the num-
ber of infectious contacts an individual can make in a single day is proportional
to SI/N , where S and I are the number of susceptible and infected individuals
respectively and N is the total population. We assume an average of 3.5 days
between exposure and becoming infectious [12].
2.3 Optimisation
The rates of progression and regression between the CIN stages is unknown,
therefore these were targeted for optimisation together with the contact rate
(Cr) and the rate of developing immunity to strains 16 & 18 (Immunity). Domain
knowledge was used to set appropriate upper and lower bounds for these rates.
The target data was extracted from Kavanagh et al. [6] (HPV, 7 years population
sampling) and Pollock et al [9] (CIN, 5 years population sampling).
Four separate experiments were carried out:
1. two-stage optimisation where infection parameters Cr, Immunity were ob-
tained by a parameter sweep followed by CIN parameters CIN1, CIN1r, CIN2,
CIN2r CIN3, CIN3r obtained using a GA,
2. two-stage optimisation as 1. but using PSO,
3. one-stage optimisation of all eight unknown parameters using a GA,
4. one-stage optimisation as 3. using PSO.
Our goal is to explore the potential use of GA and PSO with algorithm param-
eters that allow for a balance of exploration versus exploitation and that could
be completed on our local compute cluster in a reasonable time (e.g. 1 day). The
GA used a population of 100 individuals over 100 generations, with tournament
selection (5% tournament pool), 1% elitism, 1-point crossover (100%), 5% muta-
tion rate, and generational replacement. The PSO used 100 epochs, 100 particles,
0.728844 inertia, 1.49 cognitive component and 1.49 social component. For this
comparison standard parameter settings were used. Ideally we would adjust the
GA/PSO parameters to make the search process more efficient. We have mod-
erated for this by using long runs and repeating the runs. Given the number of
independent valid solutions we generated that converged to similar fitness scores,
we can be reasonably confident that our solution set is appropriate. Optimising
the algorithm parameters first may have resulted in quicker convergence but
this had to be balanced with the time taken to find these best-case algorithm
parameters. If our solution set had been more diverse and had not been a good
fit to the data then we would have refined our algorithm parameters.
For both the GA and the PSO, inputs to be optimised were internally rep-
resented by real values as used by the HPV model. Prevalence data for HPV in
Scotland [6] provides relevant target values at fixed points over time. For both
optimisers, fitness was calculated as the Euclidean distance score between the
data and the equivalent predicted model values. This was chosen as a straight-
forward standard linear measure for this data. Fixed data points in years 2009,
2010, 2012, 2013 and 2015 were used. See Figs. 2 and 3 for the fixed point values
and a comparison trace produced by a high fitness simulation. For each algo-
rithm, results were collated over 100 independent runs (i.e. 10,000 solutions),




To illustrate optimisation results against historical data, the best match trace
is shown in Figs. 2 and 3 (GA two-stage results). Mean, median and standard
deviation for all eight parameters across twenty best-fit solutions are shown in
Tab. 1, comparing GA and PSO results, and two- and one-stage processes.
Results are largely equivalent in terms of fit but there is considerable vari-
ation in some parameter values in these solutions. Distribution and correlation
information (Figs. 4–7) draw out the model’s susceptibility to variance in these
parameters. Where there is a strong correlation, the model produces a consistent
response and is sensitive to a parameter’s value. Where there is little to no cor-
relation, the model is insensitive to the parameter with respect to overall fitness.
Fig. 2. A single, best-match stochastic simulation of HPV 16 & 18 infections parame-
terised from the two-stage process showing the data points and 95% confidence intervals
of the original data
Fig. 3. A single, best-match stochastic simulation of CIN stages parameterised from
the two-stage process
Table 1. Optimised parameter values with mean and standard deviation, comparing
two- and one-stage, and GA and PSO (see also Figs. 4–7 diagonals).
Bounds Two Stage
Parameter Lower Upper GA PSO
Cr 0.03 0.06 0.0420 ±0.00045 0.0420 ±0.00045
Immunity 0.00014 0.0204 0.0028 ±0.00003 0.0028 ±0.00003
CIN1 0.01 0.90 0.65 ±0.206 0.88 ±0.019
CIN2 0.01 0.90 0.02 ±0.013 0.54 ±0.192
CIN3 0.01 0.90 0.45 ±0.288 0.79 ±0.036
CIN1r 0.01 0.90 0.39 ±0.263 0.47 ±0.286
CIN2r 0.01 0.90 0.39 ±0.212 0.79 ±0.037
CIN3r 0.01 0.90 0.46 ±0.254 0.50 ±0.286
Bounds One Stage
Parameter Lower Upper GA PSO
Cr 0.03 0.06 0.0500 ±0.00005 0.049 ±0.00065
Immunity 0.00014 0.0204 0.0015 ±0.00045 0.003 ±0.00004
CIN1 0.01 0.90 0.90 ±0.127 0.90 ±0.001
CIN2 0.01 0.90 0.01 ±0.007 0.34 ±0.322
CIN3 0.01 0.90 0.51 ±0.238 0.90 ±0.002
CIN1r 0.01 0.90 0.46 ±0.224 0.59 ±0.323
CIN2r 0.01 0.90 0.49 ±0.223 0.80 ±0.227
CIN3r 0.01 0.90 0.58 ±0.268 0.53 ±0.265
Figs. 4–7 illustrate the relationship between fitness and the other variables for
GA: two-stage, GA: one-stage, PSO: two-stage and PSO: one-stage respectively.
These figures are quite complex, so we explain the format here, and repeat the
main features in the captions to aid the reader.
The x-axes labels alternate on the top and the bottom, while the y-axes
labels alternate on the left and the right. The variables under optimisation are
labelled along the diagonal from top left to bottom right. Each position on this
diagonal includes a histogram of the named variable’s distribution of values in
the solution set of top twenty results. For example, the distribution of CIN1r is
skewed to the left in Fig. 4 but to the right in Figs. 5–7.
The bottom left section of the figures show scatter plots of pairs of variables.
Track vertically and horizontally to locate the relevant pair: for example, in
Fig. 4 the scatter plot second row from top, first column from left shows strong
correlation of fitness against CIN1.
The upper right side of the figure shows the corresponding correlation values
for the scatter plots from the lower left section. For example, in Fig. 4 the plot of
CIN2 against CIN2r (5th row, 4th column) shows a strong correlation, and this
matches a correlation value of 1.00 (4th row, 5th column).
Figs. 4–7 highlight robustness, i.e. likely model response to small changes in
parameter values. While both the GA and PSO approaches have some variables
with low pairwise correlations, the GA had slightly better variable to fitness
correlation values. Results were broadly similar for the GA across the 1-stage
















































































































































































































































































































































































































































































Fig. 4. GA parameter correlations: two-stage. Variables under optimisation are labelled
along the diagonal from top left to bottom right. Each position on this diagonal includes
a histogram of the named variable’s distribution of values. The bottom left section of
the figure shows scatter plots of pairs of variables. The upper right side of the figure
shows the corresponding correlation values for those scatter plots. The x-axes labels
















































































































































































































































































































































































































































































































































































































































































Fig. 5. GA parameter correlations: one-stage. Variables under optimisation along the
diagonal. Bottom left shows scatter plots of pairs of variables. Upper right side shows
the corresponding correlation values. X-axes labels alternate top and bottom. Y-axes

























































































































































































































































































































































































































































Fig. 6. PSO parameter correlations: two-stage. Variables under optimisation along the
diagonal. Bottom left shows scatter plots of pairs of variables. Upper right side shows
the corresponding correlation values. X-axes labels alternate top and bottom. Y-axes


















































































































































































































































































































































































































































































Fig. 7. PSO parameter correlations: one-stage. Variables under optimisation along the
diagonal. Bottom left shows scatter plots of pairs of variables. Upper right side shows
the corresponding correlation values. X-axes labels alternate top and bottom. Y-axes
labels alternate on left and right.
In contrast, the PSO seems more sensitive to the Cr and Immunity parameters
in the 2-stage process.
3.2 Clustering the Optimal Solutions
Several experiments were carried out using k-means clustering to further inves-
tigate the relationships between the produced optimal solutions. Clustering was
applied to analyse the stability of the GA results only, and of the PSO results
only. Finally, clustering was applied to GA and PSO results across the 1-stage
or 2-stage process to demonstrate which technique produced more stable so-
lutions. Values of k from 2-5 were tried. Euclidean distance was used as the
distance function, with k=3 producing optimal clusters. Distribution of data
points across clusters were monitored to provide insight into how k-means splits
the data for each k and for each optimisation approach. Cluster sizes are more
unequal for k=3. For the other values 2,4 and 5 the number of instances are more
equally distributed across clusters and therefore do not provide any additional
information.
Tab. 2 shows the results of using k-means clustering (k=3) on the combined
GA and PSO results for 1-stage or 2-stage optimisation. Clustering across the
approaches highlights the similarity of solutions produced within each method.
All 20 GA results are in cluster 0 (1-stage optimisation). All 20 PSO instances
are in cluster 0 (2-stage optimisation), highlighting sensitivity to Cr, Immunity.
Table 2. Clustering of GA and PSO solutions (1-stage left, 2-stage right).
Centroids
1-stage GA&PSO solutions 2-stage GA&PSO solutions
Attribute All Cluster0 Cluster1 Cluster2 All Cluster0 Cluster1 Cluster2
Cr 0.0494 0.05 0.0484 0.0496 0.042 0.042 0.042 0.042
Immunity 0.0023 0.0015 0.0032 0.0032 0.0028 0.0028 0.0028 0.0028
CIN1 0.90 0.90 0.90 0.90 0.76 0.56 0.81 0.88
CIN1r 0.17 0.0083 0.31 0.38 0.27 0.0092 0.0266 0.51
CIN2 0.71 0.51 0.90 0.90 0.62 0.41 0.49 0.79
CIN2r 0.53 0.46 0.75 0.37 0.43 0.35 0.40 0.49
CIN3 0.64 0.49 0.75 0.87 0.58 0.47 0.16 0.78
CIN3r 0.56 0.58 0.46 0.64 0.48 0.57 0.19 0.51
3.3 Model Predictions
Having optimised the model to match data [6, 9], predictions of vaccination poli-
cies can be made. For example, a gender-neutral policy of vaccination is clearly
equitable. Fig. 8 shows the predicted results of the gender-neutral policy and how
it produces elimination of the vaccine-specific virus strains, elimination of cross-
protected strains, and subsequent reduction of CIN with concomitant decrease
in cervical cancer. As gender-neutral vaccination was partly (due to COVID-19)
implemented in Scotland from 2019 these predictions will soon be able to be
tested against observed data.
With no vaccination, the model suggests half of the population will be in-
fected with HPV strains 16 & 18, and 31, 33 & 45. Female-only vaccination,
shown in Fig. 8 (a), reduces HPV 16 & 18 prevalence to 6% (female) and 15%
(male) of the population. In contrast, Fig. 8 (c) shows these strains are virtu-
ally eliminated with equal vaccination. Fig. 8 (a, c) shows that strains HPV 31,
33 & 45 also reduce due to cross-protection from the bivalent vaccine. If that
cross-protection wanes over time, e.g. Fig. 8 (b) shows 9.4 years protection, then
strains 31, 33 & 45 become dominant in a female-only vaccination regime with
10% females and 23% males infected. Equal vaccination eliminates these strains,
shown in Fig. 8 (d).
4 Conclusion
Two computational intelligence techniques were used to refine a hand-built
model of HPV and subsequent CIN stages. We originally took a two-stage ap-
proach with two different optimisation algorithms to cross-compare results and
parameter variance. A further one-stage 8-parameter optimisation run for the
the GA and PSO approaches was performed at the end of the study to investi-
gate if this would lead to similar results. Clustering was used to provide further
insight into the results generated.
Comparing GA performance to PSO performance, we see, as expected, the
GA is more explorative (slightly wider range of fit results in Tab. 1 and Figs. 4
and 5) and a good general-purpose heuristic. The one-stage process provides
strong correlations between CIN progression and regression parameters. The
GA pulled out an interesting and unexpected strong positive correlation between
Immunity and CIN1r: the state fImmune can be reached either directly from fInf,
or via CIN1. Clustering shows the similarity of top GA results for the one-stage
process.
For PSO the solutions (Figs. 6 and 7) showed no clear correlations between
parameters except Cr and Immunity in the one-stage optimisation. Variance was
lower overall in PSO results between one-stage and two-stage experiments. Clus-
tering shows that the top PSO results are similar for the two-stage process: PSO
gives a more uniform solution set when additional constraints are applied.
In future work, a range of algorithm parameters could be explored to improve
GA or PSO performance. GA performance could most obviously be improved
by running for longer, and decreasing mutation as the number of generations
increases. The current work sets a baseline for such experiments.
The refined model can now be used to make computational predictions from
health care data sets relating to gender policies on the bivalent vaccine. Varying
vaccine efficacy or uptake would determine potential critical vaccination thresh-
olds to ensure long-term eradication of relevant cancers. To calibrate our model
we have used data relating to HPV in Scotland; however, due to a worldwide
effort to eliminate cervical cancer, several data sets are available to validate such
models. Future work will develop our model to apply to a range of data sets,
testing predictions across vaccination scenarios, allowing more robust statistical
analysis of the results. This would provide a contrast with the results of Simms
et al [14].
Much further predictive work is possible if the model is extended, for ex-
ample, with additional HPV strains and different vaccines. In addition, there
is evidence that HPV vaccination for males can reduce head and neck cancers.
Given appropriate data, it would be of value to show the impact of vaccination
and screening on both males and females with respect to a variety of cancers.
References
1. D. Marco, D. Cairns and C. Shankland, “Optimisation of process algebra models
using evolutionary computation” in 2011 IEEE Congress of Evolutionary Compu-
tation (CEC), pp. 1296–1301, 2011.
2. D. Hamami et al., “Improving process algebra model structure and parameters in
infectious disease epidemiology through data mining”. J. Intelligent Information
Systems: 52 (3), pp. 477–499, 2019. https://doi.org/s10844-017-0476-1
3. R. Faridi et al, “Oncogenic potential of Human Papillomavirus (HPV) and its
relation with cervical cancer.” Virology Journal, vol. 8, pp. 269, BioMed Central.
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Fig. 8. Predicted impact on HPV 16 & 18, and cross-protected strains HPV 31, 33 &
45 generated by Ordinary Differential Equation-based simulation. Female vaccination
from 2008 (all plots). Equal vaccination from 2019 (c, d). Waning immunity to cross-
protected strains (b, d)
